Vyome Holdings Inc Dossier
Qualitative Analysis
Business overview
Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing next-generation therapeutic solutions for immuno-inflammatory and rare diseases of unmet medical need. Following its strategic reverse merger with Vyome Therapeutics in August 2025, the company operates a unique business model leveraging the US-India innovation corridor to achieve hyper-capital-efficient drug development. Vyome's lead clinical asset is VT-1953, a novel, patented topical gel formulation of besifloxacin designed to treat the distressing symptoms of malignant fungating wounds (MFW) in advanced cancer patients, such as severe malodor, pain, and inflammation. Additionally, the company's pipeline includes VT-1908, a pre-IND stage non-steroidal ophthalmic eye drop targeting IMPDH for anterior uveitis, and VB-1953, a Phase 2-ready topical treatment for moderate-to-severe drug-resistant inflammatory acne.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic shift focusing on the acquisition and in-licensing of commercial-stage and clinical-stage assets in the dermatology, respiratory, and immuno-inflammatory sectors to transition from a pre-revenue biotech to a diversified holding company.
Expected impact: Aims to generate immediate revenue streams and expand the therapeutic pipeline while minimizing cash burn.
Leveraging the company's unique positioning to source high-quality, preclinical and clinical-stage assets from India and develop them for global markets, utilizing cost-efficient clinical development pathways in India.
Expected impact: Significantly reduces R&D expenses compared to US-only peers, extending the cash runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of substantially all assets of Oculo, Inc., an MIT AI spinout, to launch a new business unit focused on developing AI solutions (such as an AI psychiatrist) to diagnose and treat systemic inflammation by targeting behavioral drivers and biomarkers.
Financial impact: Undisclosed transaction value; structured to not affect progress or funding of core biotech assets.
Vyome's subsidiary, LiveChain, Inc. (LICH), acquired a senior secured convertible note of Humanyze from Remus Capital in exchange for LICH common stock. LiveChain subsequently initiated a default and asset transfer to assume all business assets, IP, and operations of Humanyze, entering the AI-enabled HR analytics market.
Financial impact: All-stock transaction valued at approximately $325,000 in LICH shares. Does not consume Vyome's operational cash, but positions Vyome (as majority shareholder of LICH) to benefit from equity value creation.
Strategic Partnerships
Grants Vyome exclusive global rights to develop and commercialize two next-generation selective JAK inhibitor assets (a JAK1/3 inhibitor and a JAK1 inhibitor), opening access to a $57 billion global market.
Terms: Highly capital-efficient structure with no upfront or milestone payments; consideration is tied to commercialization, with future development planned through non-dilutive pathways.
Non-binding collaboration to jointly explore opportunities and develop AI-enabled medical devices, combining Vyome's global market access with Embryyo's medical technology capabilities.
Terms: Non-binding MoU; specific financial terms are subject to definitive agreements.